• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

勘误：依达拉奉右莰醇治疗通过抑制蛛网膜下腔出血后4-羟基壬烯醛相关的氧化应激减轻神经元凋亡并改善神经功能。

Corrigendum: Edaravone dexborneol treatment attenuates neuronal apoptosis and improves neurological function by suppressing 4-HNE-associated oxidative stress after subarachnoid hemorrhage.

作者信息

Chen Qian, Cai Yichen, Zhu Xiaoyu, Wang Jing, Gao Feng, Yang Mingfeng, Mao Leilei, Zhang Zongyong, Sun Baoliang

机构信息

The Second Affiliated Hospital, Brain Science Institute, School of Basic Medical Sciences of Shandong First Medical University and Shandong Academy of Medical Sciences, Taian, China.

出版信息

Front Pharmacol. 2024 Dec 11;15:1508703. doi: 10.3389/fphar.2024.1508703. eCollection 2024.

DOI:10.3389/fphar.2024.1508703
PMID:39723249
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11668960/
Abstract

[This corrects the article DOI: 10.3389/fphar.2022.848529.].

摘要

[本文更正了文章的数字对象标识符：10.3389/fphar.2022.848529。]

相似文献

1
Corrigendum: Edaravone dexborneol treatment attenuates neuronal apoptosis and improves neurological function by suppressing 4-HNE-associated oxidative stress after subarachnoid hemorrhage.勘误：依达拉奉右莰醇治疗通过抑制蛛网膜下腔出血后4-羟基壬烯醛相关的氧化应激减轻神经元凋亡并改善神经功能。
Front Pharmacol. 2024 Dec 11;15:1508703. doi: 10.3389/fphar.2024.1508703. eCollection 2024.
2
Edaravone Dexborneol Treatment Attenuates Neuronal Apoptosis and Improves Neurological Function by Suppressing 4-HNE-Associated Oxidative Stress After Subarachnoid Hemorrhage.依达拉奉右莰醇治疗通过抑制蛛网膜下腔出血后4-HNE相关氧化应激减轻神经元凋亡并改善神经功能。
Front Pharmacol. 2022 Apr 21;13:848529. doi: 10.3389/fphar.2022.848529. eCollection 2022.
3
Edaravone dexborneol regulates γ-aminobutyric acid transaminase in rats with acute intracerebral hemorrhage.依达拉奉右莰醇调节急性脑出血大鼠γ-氨基丁酸转氨酶。
J Stroke Cerebrovasc Dis. 2024 Jul;33(7):107738. doi: 10.1016/j.jstrokecerebrovasdis.2024.107738. Epub 2024 May 1.
4
Edaravone dexborneol attenuates oxidative stress in experimental subarachnoid hemorrhage via Keap1/Nrf2 signaling pathway.依达拉奉右莰醇通过Keap1/Nrf2信号通路减轻实验性蛛网膜下腔出血中的氧化应激。
Front Pharmacol. 2024 May 30;15:1342226. doi: 10.3389/fphar.2024.1342226. eCollection 2024.
5
Potential of Edaravone Dexborneol in the treatment of cerebral ischemia: focus on cell death-related signaling pathways.依达拉奉右莰醇在治疗脑缺血中的潜力：聚焦于细胞死亡相关信号通路。
Mol Biol Rep. 2024 Sep 23;51(1):1007. doi: 10.1007/s11033-024-09952-1.
6
Edaravone dexborneol protects cerebral ischemia reperfusion injury through activating Nrf2/HO-1 signaling pathway in mice.依达拉奉右莰醇通过激活 Nrf2/HO-1 信号通路保护脑缺血再灌注损伤。
Fundam Clin Pharmacol. 2022 Oct;36(5):790-800. doi: 10.1111/fcp.12782. Epub 2022 May 4.
7
Edaravone dexborneol exerts anti-epileptic effects on rodent temporal lobe epilepsy by promoting NMDAR deactivation and inhibiting oxidative stress.依达拉奉右莰醇通过促进NMDAR失活和抑制氧化应激对啮齿类动物颞叶癫痫发挥抗癫痫作用。
Phytomedicine. 2025 May;140:156558. doi: 10.1016/j.phymed.2025.156558. Epub 2025 Mar 1.
8
Edaravone Dexborneol Alleviates Cerebral Ischemic Injury via MKP-1-Mediated Inhibition of MAPKs and Activation of Nrf2.依达拉奉右莰醇减轻脑缺血损伤通过 MKP-1 介导的 MAPKs 抑制和 Nrf2 的激活。
Biomed Res Int. 2022 Sep 6;2022:4013707. doi: 10.1155/2022/4013707. eCollection 2022.
9
Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis.基于网状Meta分析的神经保护药物治疗急性缺血性脑卒中患者的疗效分析
Front Pharmacol. 2024 Nov 7;15:1475021. doi: 10.3389/fphar.2024.1475021. eCollection 2024.
10
Combined Selective Endovascular Brain Hypothermia with Edaravone Dexborneol versus Edaravone Dexborneol Alone for Endovascular Treatment in Acute Ischemic Stroke (SHE): Protocol for a Multicenter, Single-Blind, Randomized Controlled Study.联合选择性血管内脑低温与依达拉奉右莰醇对比单独使用依达拉奉右莰醇用于急性缺血性卒中血管内治疗（SHE）：一项多中心、单盲、随机对照研究方案
Cerebrovasc Dis. 2024 Oct 18:1-7. doi: 10.1159/000542011.